Grants for Small businesses - Federal

Grant Title: Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) aims to support the development and testing of integrated healthcare models that combine HIV/AIDS, Hepatitis, addiction treatment, and primary care services to improve health outcomes for individuals at risk for or living with these conditions.

This grant provides funding for research and initiatives that address the impacts of drought and climate change, aiming to enhance resilience and inform decision-making for communities and ecosystems across the United States.

The PRMRP Discovery Award is intended to support innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research but must be novel and must be based on a strong scientific rationale and a well-developed study design and plan of analysis. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation or product development. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.This award is not intended to support/validate ongoing research and inclusion of preliminary data is not allowed. Inclusion of preliminary data other than serendipitous finding is not consistent with the exploratory nature of this award. Applicants seeking funding for research to further an existing research project should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.

This funding opportunity supports researchers in developing and testing innovative medical devices aimed at treating or diagnosing conditions affecting the nervous and neuromuscular systems.

This funding opportunity supports multidisciplinary teams in developing innovative bioengineering technologies to address specific biomedical challenges, with eligibility for a wide range of organizations including universities, nonprofits, and small businesses.

This funding opportunity provides financial support to various organizations to develop and implement evidence-based self-management programs that improve health knowledge and reduce complications for individuals affected by blood disorders like hemophilia and thalassemia.

The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications encouraging foundational research projects that seek to refine and test valid methods for characterizing preteen suicide risk and protective factors across multiple domains, and for operationalizing suicide thoughts and behavior (STBs) and nonsuicidal self-injury (NSSI) among preteen youth (ages 8-12). An emphasis is placed on the inclusion of sub-populations of youth that experience health disparities and may have been underrepresented in prior youth suicide research. Studies may focus on developing new or adapting developmentally and culturally appropriate methods for assessing and characterizing risk and protective factors, examining the acceptability and utility of existing assessment methods, evaluating the relevance of risk and protective factors for diverse preteen youth and their families, modeling risk-factor trajectories, and refining sampling strategies. The research projects funded through this announcement will participate in a research consortium with other R01 recipients. In addition, each research site will work with the Data Coordinating Center (DCC) site (supported by a companion announcement) to share and analyze data, recommend candidate measures that will be included as common data elements in future research and practice contexts,and identify optimal approaches for sampling individuals from underrepresented backgrounds. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects, and to consult with NIH in order to submit responsive applications. The NOFO is expected to be published in Summer 2023, with an expected application due date in Fall 2023. This NOFO will utilize the R01 activity code. Details of the planned NOFO are provided below.

This funding opportunity supports research projects that develop and implement effective strategies to reduce overdose deaths and improve addiction treatment across various settings, targeting diverse populations and addressing health disparities.

This grant provides funding for researchers and organizations to develop innovative medical countermeasures for treating acute chemical exposures resulting from terrorist attacks or accidental releases, enhancing national preparedness for chemical emergencies.

This funding opportunity supports innovative research projects aimed at making significant advancements in breast cancer prevention, diagnosis, and treatment, involving collaboration with breast cancer survivors as advocates.

This funding opportunity provides financial support for researchers and organizations developing innovative long-acting treatments for HIV and related co-infections, aiming to improve patient adherence and health outcomes.

The Small Business Innovation Research (SBIR) Program for CHIPS for America CHIPS Metrology seeks applications from eligible applicants to explore the technical merit or feasibility of an innovative idea or technology with the aim of developing a viable product or service that will be introduced to the commercial microelectronics marketplace. This NOFO contains multiple topics on research projects for critically needed measurement services, tools, and instrumentation; innovative manufacturing metrologies; novel assurance and provenance technologies and advanced metrology research and development (R) testbeds to help secure U.S. leadership in the global semiconductor industry.

This funding opportunity supports innovative research aimed at developing new strategies for curing HIV at the start of antiretroviral therapy, targeting researchers and institutions focused on reducing the HIV reservoir and improving immune responses.

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

This funding opportunity provides financial support to organizations working to improve laboratory diagnostics and monitoring for HIV/AIDS care and treatment in Jamaica and Trinidad and Tobago, enhancing public health outcomes in the Caribbean.

This funding opportunity supports small businesses in developing innovative projects that improve the lives of individuals with disabilities, focusing on community living, health, and employment accessibility.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity provides $5 million to support the deployment and commercialization of innovative technologies in public transportation, aimed at federal, state, local, and tribal governments, as well as public transit providers and educational institutions.

The National Aeronautics and Space Administration (NASA) Headquarters has released a solicitation, titled Early Stage Innovations (ESI), as an appendix to the Space Technology Mission Directorate (STMD) umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2024 (SpaceTech REDDI 2024), on April 4, 2024. The ESI solicitation is available by opening the NSPIRES homepage at https://nspires.nasaprs.com/, selecting Open under "Solicitations," and searching "Early Stage Innovations (ESI24)" under Keywords. The Space Technology Research Grants (STRG) Program within STMD seeks proposals from accredited U.S. universities to develop unique, disruptive, or transformational space technologies that have the potential to lead to dramatic improvements at the system level performance, weight, cost, reliability, operational simplicity, or other figures of merit associated with spaceflight hardware or missions. The projected impact at the system level must be substantial and clearly identified. Only accredited U.S. universities are eligible to submit proposals. Teaming is permitted see solicitation for complete eligibility requirements as well as teaming restrictions. A Principal Investigator (see solicitation for restrictions) or Co-Investigator may participate in no more than two proposals in response to this solicitation. NASA encourages submission of ESI proposals on behalf of tenure-track or tenured faculty members at all U.S. universities and especially encourages proposals submitted on behalf of and/or that include as team members women, members of underrepresented minority groups, and persons with disabilities. The solicitation exclusively seeks proposals that are responsive to one of the following two topics: Topic 1 Computational Materials Engineering for Lunar Metals Welding Topic 2 Passive Lunar Dust Control through Advanced Materials and Surface Engineering NASA anticipates addressing other topics in future ESI Appendix releases. The financial and programmatic support for ESI comes from the Space Technology Research Grants Program within the Space Technology Mission Directorate. Awards are planned to start in January 2025. NASA plans to make approximately 6 awards as a result of this ESI solicitation, subject to the receipt of meritorious proposals. The actual number of awards will depend on the quality of the proposals received; NASA reserves the right to make no awards under this solicitation. STMD is strongly committed to ensuring that proposal review is performed in an equitable and fair manner that reduces the impacts of any unconscious biases. To this end, this Appendix will employ a Dual-Anonymous Peer Review (DAPR) process to evaluate proposals. Using DAPR, not only are proposers not told the identities of the reviewers, but the identities of the proposers (personnel and organization names) will not be shared with the reviewers until after the technical review of all anonymized proposals has been completed. All proposals must be submitted electronically through NSPIRES by an authorized organizational representative. Notices of Intent (strongly encouraged) are due by May 9, 2024, with proposals due on or before June 6, 2024, 5 pm Eastern. Detailed submission instructions and due dates are provided in the solicitation. Potential proposers and their proposing organizations are urged to familiarize themselves with the submission system, ensure they are registered in NSPIRES, and submit the required proposal materials well in advance of the deadline. All technical and programmatic comments and questions may be addressed by email to the Space Technology Research Grants Program Executive, at [email protected]. Responses to inquiries will be answered by email and may also be included in the Frequently Asked Questions (FAQ) documents located on the NSPIRES page associated with the solicitation; anonymity of persons/institutions who submit questions will be preserved.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.